SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Drug Development
Healthcare at a Crossroads: Maintaining Good Science in Uncertain Times
Continuing our SCOPE 2025 coverage, Rohit Nambisan, CEO at Lokavant addresses not only current challenges, but the life sciences industry’s responsibility to maintain scientific integrity.
February 17, 2025
 · 
1 min read
 · 
Lori Ellis
Mushrooms and mental health as Psychedelic drug or psychedelics hallucinogenic drugs and hallucinogens representing medicine for brain disorders in a 3D illustration style.
Psychedelics
Psychedelics Space Regroups as RFK Jr. Signals Support
After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a recent approval and positive data are generating new momentum, which experts expect to continue throughout 2025 and 2026.
February 17, 2025
 · 
5 min read
 · 
Heather McKenzie
Businessman climbed the clouds to see the distance
Immunology and Inflammation
I&I Investment Ramps Up With Novel Targets and Boundless Opportunity
Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options in inflammatory bowel disease, atopic dermatitis, myasthenia gravis and more.
February 17, 2025
 · 
5 min read
 · 
Kate Goodwin
x-ray wrist muscle pain in gray background
Opinion
Companies Take Multiple Tacks Against Myotonic Dystrophy Type 1
With its recent data drop for an oligonucleotide candidate, Dyne Therapeutics signals it may become a frontrunner in this disease space alongside Avidity Biosciences, Lupin and AMO Pharma.
February 17, 2025
 · 
4 min read
 · 
Jia Jie Chen
Composite photo collage of massive hairy hands hold wad money count dollars earnings income wealth isolated on painted background.
Immunology and Inflammation
I&I Startup Bambusa Nabs $90M for Bispecific Antibodies
The company, helmed by BioNTech alums, is developing therapies aimed at dermatological, respiratory and gut-related indications.
February 14, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Pictured: Facade of Moderna's building in Massachusetts
Earnings
Moderna Reports Higher-Than-Expected Losses While Anticipating Layoffs
In its fourth-quarter earnings report, Moderna’s revenue was down substantially from 2023. Separately, media reports reveal anticipated cuts to the company’s digital team.
February 14, 2025
 · 
3 min read
 · 
Tristan Manalac
Pictured: BMS sign on a building in San Diego, California/iStock, JHVEPhoto
Cancer
BMS’ Phase III Opdualag Melanoma Fail Could Limit Market Opportunity: Analysts
The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts.
February 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Two hands locked in a handshake cut by a pair of scissors, symbolizing a severed relationship or partnership. Black and white collage illustration on paper textured background
Collaboration
Amgen, Ideaya Call It Quits on Cancer Combo
Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in MTAP-null advanced non-small cell lung cancer.
February 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Speech balloon conversation in puzzle shape vector illustration card. Human hands exchange information in retro 80s collage vector illustration. Concept of success in communication, support, cooperation; new projects, professional growth.
Immunology and inflammation
Pliant Brings in Outside Experts to Review IPF Study Pause
The experts will assess unblinded data from BEACON-IPF to figure out why a data safety monitoring board recommended suspension of the idiopathic pulmonary fibrosis trial.
February 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS